WO2021213311A1 - Immunofluorescence kit for detecting pd-l1 gene expression of patient with colorectal cancer by means of peripheral blood circulating tumor cells - Google Patents
Immunofluorescence kit for detecting pd-l1 gene expression of patient with colorectal cancer by means of peripheral blood circulating tumor cells Download PDFInfo
- Publication number
- WO2021213311A1 WO2021213311A1 PCT/CN2021/088072 CN2021088072W WO2021213311A1 WO 2021213311 A1 WO2021213311 A1 WO 2021213311A1 CN 2021088072 W CN2021088072 W CN 2021088072W WO 2021213311 A1 WO2021213311 A1 WO 2021213311A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peripheral blood
- tumor cells
- filter
- colorectal cancer
- labeled goat
- Prior art date
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 55
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 42
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 42
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 37
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 37
- 230000014509 gene expression Effects 0.000 title claims abstract description 25
- 238000010166 immunofluorescence Methods 0.000 title claims abstract description 15
- 241000283707 Capra Species 0.000 claims abstract description 35
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 32
- 239000000725 suspension Substances 0.000 claims abstract description 22
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims description 27
- 239000012192 staining solution Substances 0.000 claims description 23
- 238000005374 membrane filtration Methods 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical group C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000004042 decolorization Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 238000002738 Giemsa staining Methods 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 210000005266 circulating tumour cell Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- -1 GPC-3 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000011897 real-time detection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Definitions
- the invention provides an immunofluorescence kit and a detection method for PD-L1 gene expression in peripheral blood circulating tumor cells of patients with colorectal cancer, and belongs to the technical field of molecular biology.
- Colorectal cancer is one of the most common malignant tumors in the world, and the mortality rate in 2018 ranked fourth among malignant tumors. In the United States, colorectal cancer is the third most common malignant tumor. Domestically, China's annual epidemiological data in 2018: the incidence and mortality of colorectal cancer are both the fifth, with 376,300 new cases per year, and 25% of them have metastasized when they are diagnosed. Colorectal cancer is mostly asymptomatic in the early stage, and most of the symptoms appear in the middle and late stages with metastasis. Despite continuous innovations in surgical procedures and chemotherapy, the survival rate of patients with advanced colorectal cancer is still very poor. Due to the lack of better prevention methods for colorectal cancer, the most effective way to improve the prognosis of colorectal cancer and increase the survival rate is to diagnose and treat early colorectal cancer and precancerous lesions.
- Immunotherapy with PD-1/PD-L1 as the immune target has brought a new dawn for the treatment of colorectal cancer.
- Tumor cells can bind to PD-1 on the surface of immune cells and T cells through PD-L1 on their surface, and conduct inhibitory signals to make T cells The inability to recognize tumor cells and send out attack signals to tumor cells leads to immune escape of tumor cells.
- CTC circulating tumor cells
- the efficacy of PD-1 or PD-L1 immune preparations is mostly related to the immunohistochemical expression level of PD-L1 in tumor tissues, suggesting that the expression level of PD-L1 may be a biomarker predicting the efficacy of PD-1 immunotherapy; current colorectal
- the detection of PD-L1 in cancer circulating tumor cells has not been reported at home and abroad. Therefore, detecting the expression of circulating tumor cells (CTC) PD-L1 has important value for the prognosis of colorectal cancer and the evaluation of immunotherapy efficacy.
- CTC circulating tumor cells
- Circulating tumor cells are tumor cells that fall off from solid tumors and enter the peripheral blood circulation. Since they were discovered in 1989, there have been a variety of methods for detecting circulating tumor cells in the peripheral blood. Recent studies have shown that its detection has important clinical significance for evaluating the prognosis of cancer patients, especially advanced cancer patients, and selecting appropriate individualized treatments. Because CTC detection has the characteristics of minimally invasive and real-time detection, it is called "liquid biopsy" of tumors.
- Immunofluorescence analysis technology combines immunological methods (antigen-antibody specific binding) and fluorescent labeling technology to study the method of specific protein antigen distribution in cells. Because the fluorescence emitted by fluorescein can be detected under a fluorescence microscope, fluorescein emits bright fluorescence (yellow-green or orange-red) when irradiated by the excitation light, and the cells or tissues where the fluorescence is located can be seen. Quantitative techniques are used to determine the content. In order to carry out cell qualitative and localization analysis of the antigen.
- the specimens for PD-L1 gene detection in colorectal cancer patients are mainly tumor tissues, which are derived from surgery or needle biopsy, and it is difficult to achieve multiple or real-time detection. Therefore, the detection of circulating tumor cell (CTC) PD-L1 gene expression is of great value for the prognosis of colorectal cancer and the evaluation of the efficacy of immunotherapy.
- CTC circulating tumor cell
- Shandong First Medical University, Shandong Pharmaceutical Research Institute and Shandong Qixin Biotechnology Co., Ltd., Shandong Yuxiao Biotechnology Co., Ltd., Jinan Xingen Biotechnology Co., Ltd., Shandong Discovery Biotechnology Co., Ltd. and other units have Research on the industrialization of key technologies for tumor cell detection and identification.
- This project is a major scientific and technological innovation project in Shandong Province. This project will take the Shandong Provincial Pharmaceutical Research Institute on the Jinan Campus of Shandong First Medical University as the core and implement the registrant system.
- Circulating tumor cell detection and identification of core diagnostic technology, and further registration and identification of diagnostic kits to include PD1, PD-L1, ER, PR, Her-2, GPC-3, VEGF, P53, Vimentin, TKI-EGFR, RAS, CK, ALK-D5F3, CD20, ALK/EML4, Beta-catenin, E-Cadherin, EP-CAM, HPV, IDH-1, PSA, PSMA, VEGF, GFAP, Cytokeratin, AE1/AE3, estrogen receptor, pregnancy Hormone receptors, BCA-225, CA 125, CEA, EMA, ERCC1, HPV, Ki-67, P53, TOP2A, etc.
- the identification and diagnosis kits are industrialized and promoted through cooperation with Shandong Qixin Biotechnology Co., Ltd., Shandong Yuxiao Biotechnology Co., Ltd., Jinan Xingen Biotechnology Co., Ltd., and Shandong Discovery Biotechnology Co., Ltd., which are registered in Jinan.
- the present invention provides an immunofluorescence kit and a detection method for the expression of PD-L1 gene in circulating tumor cells in the peripheral blood of patients with colorectal cancer.
- the membrane filtration device is used to separate and obtain circulating tumor cells (CTC) in the peripheral blood of patients with advanced colorectal cancer.
- CTC circulating tumor cells
- An immunofluorescence kit for detecting PD-L1 gene expression in circulating tumor cells in the peripheral blood of patients with colorectal cancer which is characterized in that it includes 45 mL of dilution solution, 1 mL of decolorizing solution, staining solution A 0.5 mL, staining solution B 1 mL, 200 ⁇ l methanol, 200 ⁇ l 2% PFA, 100 ⁇ l 10% goat serum, 100 ⁇ l of primary antibody suspension composed of mouse anti-CK, rat anti-CD45 and rabbit anti-PD-L1 genes, fluorescent-labeled goat anti-mouse, fluorescent-labeled goat anti-rat, 100 ⁇ L of fluorescently labeled goat anti-rabbit secondary antibody suspension, DAPI mounting plate;
- mice anti-CK, rat anti-CD45 and rabbit anti-PD-L1 genes in the primary antibody suspension were diluted 1:100, 1:400, and 1:500 respectively, and the total volume was 100 ⁇ L;
- Fluorescently labeled goat anti-mouse, fluorescently labeled goat anti-rat, and fluorescently labeled goat anti-rabbit in the secondary antibody suspension were diluted 1:500.
- the diluent is composed of 1 mmol/L EDTA + 1 mmol moon silicate + 0.1% BSA + 0.2% poloxamer.
- the decolorizing liquid is composed of 95% alcohol and 100% xylene in a volume ratio of 1:1.
- the staining solution A is DAB staining solution
- the staining solution B is hematoxylin staining solution.
- the method for detecting PD-L1 gene expression in peripheral blood circulating tumor cells of patients with colorectal cancer for non-diagnostic purposes of the above kit includes the following steps:
- step (7) using immunofluorescence method to detect the expression of PD-L1 gene of peripheral blood CTC is as follows:
- the membrane filtration device used in the present invention to separate circulating tumor cells includes a filter, a blood sample container, a waste liquid tank and an iron stand.
- the iron stand is provided with a base, a stand and a bracket.
- the blood sample container is set on the upper part of the iron stand through the bracket.
- Below the blood sample container is a filter, the filter is connected to the waste liquid tank through the infusion set, and the waste liquid tank is arranged on the base.
- the filter includes a filter upper port, a filter membrane, a filter membrane platform and a filter lower port.
- the filter membrane is placed on the filter membrane platform; the upper port of the filter is connected to the blood sample container, and the lower port of the filter is connected to the waste liquid tank through the infusion device.
- the filter membrane is made of hydrophobic material, and the filter holes with a diameter of 8 microns are uniformly spread on it; the diameter of tumor cells is generally greater than 15 microns, and the diameter of blood cells (including red blood cells and white blood cells) is generally less than 8 microns, so when it contains CTC After the peripheral blood is filtered, the blood cells can be filtered because the diameter is smaller than the filter hole, and the CTC is trapped on the filter membrane because the diameter is larger than the filter hole.
- the detection method provided by the present invention can detect the PD-L1 gene expression of patients with advanced or recurrent colorectal cancer without puncture biopsy to obtain tissue samples, and can realize real-time dynamic detection by using minimally invasive technology.
- the method provided by the present invention has good separation of circulating tumor cells, can avoid the interference of blood cells, can avoid false positive results caused by the edge effect that may occur in the staining process, has good stability, reduces cell loss, and improves detection accuracy sex.
- Figure 1 is a schematic diagram of the structure of the membrane filtration device of the present invention.
- FIG. 2 is a schematic cross-sectional view of the structure of the filter of the membrane filtration device of the present invention
- FIG. 3 is a schematic diagram of the structure of the filter membrane of the membrane filtration device of the present invention.
- Figure 4 is an image diagram of circulating tumor cells obtained from peripheral blood of patients with colorectal cancer
- Figure 5 shows the PD-L1 gene immunofluorescence staining image of circulating tumor cells in the peripheral blood of patients with advanced colorectal cancer, where A is merge, B is the target gene expression (red), C is CK (green), and D is CD45 (blue).
- Component content Diluent 45mL Decolorizing liquid (volume ratio of 95% alcohol and 100% xylene 1:1) 1mL Staining solution A (DAB staining solution) 0.5mL Staining solution B (hematoxylin staining solution) 1mL 10% goat serum (diluted in PBS) 100 ⁇ L Primary antibody suspension 100 ⁇ L Secondary antibody suspension 100 ⁇ L
- the primary antibody suspension is composed of mouse anti-CK, rat anti-CD45, and rabbit anti-PD-L1 genes.
- the mouse anti-CK, rat anti-CD45, and rabbit anti-PD-L1 genes are respectively BD wash buffer at 1:100 , 1:500 and 1:400 dilution, after dilution, take 10 ⁇ L mouse anti-CK, 50 ⁇ L rat anti-CD45 and 40 ⁇ L rabbit anti-PD-L1 gene to form the primary antibody suspension;
- the secondary antibody suspension is composed of fluorescently labeled goat anti-mouse, fluorescently labeled goat anti-rat, and fluorescently labeled goat anti-rabbit. They are respectively commercially available Alexa Fluor 546 goat Anti-mouse, Alexa Fluor 488 goat Anti -rat and Alexa Fluor 647 goat Anti-rabbit, take the same amount of the above three fluorescently labeled secondary antibodies, dilute them with BD wash buffer at 1:500 and mix to obtain the secondary antibody suspension.
- the membrane filtration device is composed of a filter 3, a filter membrane 7, a blood sample container 2, a waste liquid tank 5, and an iron stand 1;
- the diameter of tumor cells is generally greater than 15 microns, and the diameter of blood cells (including red blood cells and white blood cells) is generally less than 8 microns. Therefore, after the peripheral blood containing CTC is filtered, the blood cells can be filtered because the diameter is smaller than the filter hole 10, and the CTC is larger than the diameter.
- the filter hole 10 is trapped on the filter membrane 7. What needs to be explained here is that the diluent plays the role of de-adhesion and dispersion. The laurate and poloxamer are used together to ensure that blood cells and CTC do not adhere and are fully dispersed in the diluent to effectively pass through the filter membrane. 7 was detained.
- Figure 5 is an immunofluorescence staining image of circulating tumor cells in the peripheral blood of patients with advanced hepatocellular carcinoma. According to immunological and morphological findings, it is found that the tumor cells are large in size and have abnormal nucleus-to-cytoplasmic ratios. The immunological findings are typical CTCs.
- the detected circulating tumor cells were confirmed by immunofluorescence to confirm the expression of the PD-L1 gene and compared with the results of the PD-L1 gene of colorectal cancer specimens. Observe the differences.
- the main target is that the PD-L1 gene expression of the gross specimens is negative and the circulating tumor cells are positive. Of patients, guide the targeted therapy of colorectal cancer, and provide new ideas for targeted therapy of colorectal cancer.
Abstract
Description
组分Component | 含量content |
稀释液Diluent | 45mL45mL |
脱色液(95%酒精与100%二甲苯体积比1∶1)Decolorizing liquid (volume ratio of 95% alcohol and 100% xylene 1:1) | 1mL1mL |
染色液A(DAB染色液)Staining solution A (DAB staining solution) | 0.5mL0.5mL |
染色液B(苏木素染色液)Staining solution B (hematoxylin staining solution) |
1mL |
10%山羊血清(PBS稀释)10% goat serum (diluted in PBS) | 100μL100μL |
一抗混悬液Primary antibody suspension | 100μL100μL |
二抗混悬液Secondary antibody suspension | 100μL100μL |
Claims (6)
- 一种检测结直肠癌患者外周血循环肿瘤细胞PD-L1基因表达的免疫荧光试剂盒,其特征在于,包括稀释液45mL,脱色液1mL,染色液A 0.5mL,染色液B 1mL,200μl甲醇、200μl 2%PFA,100μl 10%山羊血清,小鼠抗CK、大鼠抗CD45和兔抗PD-L1基因组成的一抗混悬液100μl,荧光标记的羊抗小鼠、荧光标记的羊抗大鼠、荧光标记的羊抗兔组成的二抗混悬液100μL,DAPI封片剂;An immunofluorescence kit for detecting PD-L1 gene expression in circulating tumor cells in the peripheral blood of patients with colorectal cancer, which is characterized in that it includes 45 mL of dilution solution, 1 mL of decolorizing solution, staining solution A 0.5 mL, staining solution B 1 mL, 200 μl methanol, 200 μl 2% PFA, 100μl 10% goat serum, 100μl of primary antibody suspension composed of mouse anti-CK, rat anti-CD45 and rabbit anti-PD-L1 genes, fluorescent-labeled goat anti-mouse, fluorescent-labeled goat anti-rat , 100μL of secondary antibody suspension composed of fluorescently labeled goat anti-rabbit, DAPI mounting plate;一抗混悬液中小鼠抗CK、大鼠抗CD45和兔抗PD-L1基因分别按1:100、1:400和1:500稀释,总体积为100μL;The mouse anti-CK, rat anti-CD45 and rabbit anti-PD-L1 genes in the primary antibody suspension were diluted 1:100, 1:400, and 1:500 respectively, and the total volume was 100 μL;二抗混悬液中荧光标记的羊抗小鼠、荧光标记的羊抗大鼠、荧光标记的羊抗兔按1:500稀释。Fluorescently labeled goat anti-mouse, fluorescently labeled goat anti-rat, and fluorescently labeled goat anti-rabbit in the secondary antibody suspension were diluted 1:500.
- 根据权利要求1所述的试剂盒,其特征在于,所述稀释液是由1mmol/L EDTA+1mmol月硅酸盐+0.1%BSA+0.2%泊洛沙姆组成。The kit according to claim 1, wherein the diluent is composed of 1 mmol/L EDTA + 1 mmol moon silicate + 0.1% BSA + 0.2% poloxamer.
- 根据权利要求1所述的试剂盒,其特征在于,所述脱色液是由95%酒精与100%二甲苯按体积比1:1组成。The kit according to claim 1, wherein the decolorizing solution is composed of 95% alcohol and 100% xylene in a volume ratio of 1:1.
- 根据权利要求1所述的试剂盒,其特征在于,所述染色液A为DAB染色液;所述染色液B为苏木素染色液。The kit according to claim 1, wherein the staining solution A is a DAB staining solution; the staining solution B is a hematoxylin staining solution.
- 一种利用权利要求1-4任一项所述的试剂盒非诊断目的检测结直肠癌患者外周血循环肿瘤细胞PD-L1基因表达的方法,其特征在于,包括以下步骤:A method for detecting PD-L1 gene expression in circulating tumor cells in peripheral blood of patients with colorectal cancer for non-diagnostic purposes using the kit of any one of claims 1 to 4, which is characterized in that it comprises the following steps:(1)利用膜过滤装置分离获取无法获得组织标本的晚期或复发结直肠癌患者外周血:采集无法获取组织标本的晚期或复发结直肠癌患者肘正中静脉外周血5ml;(1) Use membrane filtration device to separate and obtain peripheral blood of patients with advanced or recurrent colorectal cancer who cannot obtain tissue samples: Collect 5ml of peripheral blood from the median cubital vein of patients with advanced or recurrent colorectal cancer who cannot obtain tissue samples;(2)外周血样预处理:将采集的外周血样采用稀释液进行10倍稀释,稀释后加多聚甲醛固定外周血样10分钟,固定终浓度为0.25%;(2) Pretreatment of peripheral blood samples: Dilute the collected peripheral blood samples 10 times with diluent, add paraformaldehyde to fix the peripheral blood samples for 10 minutes after dilution, and fix the final concentration to 0.25%;(3)利用膜过滤分离肿瘤细胞装置过滤外周血样,分离获得外周血CTC:将预处理的外周血样加入到膜过滤分离肿瘤细胞装置的血样容器中,使其依靠重力自然过滤;(3) Use membrane filtration device to separate tumor cells to filter peripheral blood samples to separate and obtain peripheral blood CTC: add the pretreated peripheral blood sample to the blood sample container of the membrane filtration device to separate tumor cells so that it can be filtered naturally by gravity;(4)过滤结束后,从膜过滤分离肿瘤细胞装置中取下滤器,将循环肿瘤细胞染色液A液0.5ml加入到滤器中,染色3min,PBS缓冲液冲洗干净;滤液过滤完全后加入染色液B液1ml,染色2min,纯水1ml冲洗2次;(4) After filtering, remove the filter from the device for separating tumor cells by membrane filtration, add 0.5 ml of circulating tumor cell staining solution A to the filter, stain for 3 minutes, and rinse with PBS buffer; add staining solution after filtering the filtrate 1ml B solution, stain for 2min, rinse 2 times with 1ml pure water;(5)向滤器中加入200μl 2%PFA,室温固定5min,完成后0.5ml PBS漂洗3次,每次2min;(5) Add 200μl 2% PFA to the filter, fix at room temperature for 5 minutes, and rinse with 0.5ml PBS for 3 times, 2 minutes each time;(6)再向滤器中加入200μl预冷的甲醇,4℃固定15min,取下滤膜,放置在载玻片上,干燥后在显微镜下观察,确定是否存在CTC;(6) Add 200μl of pre-cooled methanol to the filter, fix it at 4°C for 15 minutes, remove the filter membrane, place it on a glass slide, and observe under a microscope after drying to determine whether there is CTC;(7)运用免疫荧光方法检测外周血CTC的PD-L1基因表达情况。(7) Use immunofluorescence method to detect the expression of PD-L1 gene in peripheral blood CTC.
- 根据权利要求5所述的检测方法,其特征在于,所述的步骤(7)运用免疫荧光方法检测外周血CTC的PD-L1基因表达的具体方法如下:The detection method according to claim 5, characterized in that, in the step (7), the specific method for detecting the expression of PD-L1 gene of peripheral blood CTC by using immunofluorescence method is as follows:(1)脱色:将带有CTC的滤膜从载玻片上取下,置于脱色液中浸泡4-6小时,脱去CTC染色液,PBS洗2min×3次;(1) Decolorization: Remove the filter membrane with CTC from the glass slide, soak it in the decolorization solution for 4-6 hours, remove the CTC staining solution, and wash with PBS for 2min×3 times;(2)封闭:向滤膜上滴加100μl 10%山羊血清,室温放置30min,完成后吸去多余的血清;(2) Blocking: Drop 100μl 10% goat serum on the filter membrane, leave it at room temperature for 30 minutes, and suck off the excess serum after completion;(3)一抗孵育:向滤膜上滴加100μl小鼠抗CK、大鼠抗CD45和兔抗PD-L1基因组成的一抗混悬液,37℃孵育1h或4℃过夜,完成后PBS洗3min×3次;(3) Primary antibody incubation: drop 100μl of mouse anti-CK, rat anti-CD45 and rabbit anti-PD-L1 gene primary antibody suspension on the filter membrane, incubate at 37°C for 1h or 4°C overnight, and then PBS Wash 3min×3 times;(4)二抗孵育:向滤膜上滴加100μl荧光标记的羊抗小鼠、荧光标记的羊抗大鼠、荧光标记的羊抗兔组成的二抗混悬液,室温孵育30min,完成后PBS洗2min×3次;(4) Secondary antibody incubation: drop 100μl of the secondary antibody suspension composed of fluorescently labeled goat anti-mouse, fluorescently labeled goat anti-rat, and fluorescently labeled goat anti-rabbit on the filter membrane, and incubate at room temperature for 30 minutes. Wash with PBS for 2min×3 times;(5)使用含DAPI的封片剂封片,阅片,采图;(5) Use DAPI-containing mounting tablets to mount, read and take pictures;(6)采照完成后,脱片后进行瑞氏吉姆萨染色,与IF结果进行对比。(6) After taking the photos, take off the pieces and perform Wright's Giemsa staining to compare with the IF results.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010319551.X | 2020-04-22 | ||
CN202010319551.XA CN111521800A (en) | 2020-04-22 | 2020-04-22 | Immunofluorescence kit for detecting gene expression of PD-L1 of colorectal cancer patient through peripheral blood circulating tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021213311A1 true WO2021213311A1 (en) | 2021-10-28 |
Family
ID=71910620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/088072 WO2021213311A1 (en) | 2020-04-22 | 2021-04-19 | Immunofluorescence kit for detecting pd-l1 gene expression of patient with colorectal cancer by means of peripheral blood circulating tumor cells |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111521800A (en) |
WO (1) | WO2021213311A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111521800A (en) * | 2020-04-22 | 2020-08-11 | 山东第一医科大学(山东省医学科学院) | Immunofluorescence kit for detecting gene expression of PD-L1 of colorectal cancer patient through peripheral blood circulating tumor cells |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105588943A (en) * | 2016-01-28 | 2016-05-18 | 山东省肿瘤防治研究院 | Detection method for peripheral blood CTC (Circulating Tumor Cell) Her-2 gene of stomach cancer patient |
CN105606823A (en) * | 2016-01-28 | 2016-05-25 | 山东省肿瘤防治研究院 | Detection method for PR genes of circulating tumor cells in peripheral blood of later-period breast cancer patient |
CN106198984A (en) * | 2016-08-22 | 2016-12-07 | 上海立闻生物科技有限公司 | The detection method of Peripheral Blood of Patients with Non-small Cell Lung circulating tumor cell PDL1 gene |
CN110632292A (en) * | 2019-06-12 | 2019-12-31 | 江苏莱尔生物医药科技有限公司 | Immunofluorescence kit for detecting PD-L1 and CD8 antigens and application method |
CN111521800A (en) * | 2020-04-22 | 2020-08-11 | 山东第一医科大学(山东省医学科学院) | Immunofluorescence kit for detecting gene expression of PD-L1 of colorectal cancer patient through peripheral blood circulating tumor cells |
-
2020
- 2020-04-22 CN CN202010319551.XA patent/CN111521800A/en not_active Withdrawn
-
2021
- 2021-04-19 WO PCT/CN2021/088072 patent/WO2021213311A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105588943A (en) * | 2016-01-28 | 2016-05-18 | 山东省肿瘤防治研究院 | Detection method for peripheral blood CTC (Circulating Tumor Cell) Her-2 gene of stomach cancer patient |
CN105606823A (en) * | 2016-01-28 | 2016-05-25 | 山东省肿瘤防治研究院 | Detection method for PR genes of circulating tumor cells in peripheral blood of later-period breast cancer patient |
CN106198984A (en) * | 2016-08-22 | 2016-12-07 | 上海立闻生物科技有限公司 | The detection method of Peripheral Blood of Patients with Non-small Cell Lung circulating tumor cell PDL1 gene |
CN110632292A (en) * | 2019-06-12 | 2019-12-31 | 江苏莱尔生物医药科技有限公司 | Immunofluorescence kit for detecting PD-L1 and CD8 antigens and application method |
CN111521800A (en) * | 2020-04-22 | 2020-08-11 | 山东第一医科大学(山东省医学科学院) | Immunofluorescence kit for detecting gene expression of PD-L1 of colorectal cancer patient through peripheral blood circulating tumor cells |
Also Published As
Publication number | Publication date |
---|---|
CN111521800A (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021213322A1 (en) | Immunofluorescence kit for detecting pd-l1 expression of peripheral blood circulating tumor cells of kidney cancer patient and detection method | |
WO2021213262A1 (en) | Immunofluorescence test kit for measuring pd-l1 expression in circulating tumor cells in peripheral blood in stomach cancer patient, and measurement method | |
WO2021213295A1 (en) | Immunofluorescence kit for detecting nse gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patient and detection method | |
WO2021213323A1 (en) | Non-diagnostic method for detecting pd-l1 gene mutation of patient with colorectal cancer by means of circulating tumor cells in peripheral blood | |
WO2021213316A1 (en) | Kit for detecting peripheral blood circulating tumor cell pd-l1 gene mutation of patient with kidney cancer, and detection method | |
WO2021213310A1 (en) | Immunofluorescence kit for detecting pd-l1 gene expression of patient with esophageal squamous cell carcinoma by means of peripheral blood circulating tumor cells | |
WO2021213315A1 (en) | Kit for detecting mutation expression of braf gene v600e of colorectal cancer patient by means of peripheral blood circulating tumor cells | |
WO2021213292A1 (en) | Immunofluorescence test kit for measuring pd-l1 expression in circulating tumor cells in peripheral blood in prostate cancer patient, and measurement method | |
WO2021213302A1 (en) | Immunofluorescence test kit for measuring cea gene mutations in circulating tumor cells in peripheral blood in non-small cell lung cancer patient, and measurement method | |
CN111638357A (en) | Immunofluorescence kit and method for E-Cadherin mutation of peripheral blood circulating tumor cells of patient with non-small cell lung cancer | |
WO2021213306A1 (en) | Test kit for measuring pd-l1 gene mutations in circulating tumor cells in peripheral blood in non-small cell lung cancer patient, and measurement method | |
CN111638359A (en) | Immunofluorescence kit and detection method for detecting PD-L1 gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients | |
WO2021213304A1 (en) | Kit for detecting nse gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patient and detection method | |
WO2022001824A1 (en) | Kit and method for detecting pd-l1 gene mutations in circulating tumor cells in peripheral blood of patient with small cell lung cancer | |
WO2021213290A1 (en) | Kit for testing expression of ca199 in circulating tumor cells in peripheral blood of patients with pancreatic cancer and testing method | |
WO2021213311A1 (en) | Immunofluorescence kit for detecting pd-l1 gene expression of patient with colorectal cancer by means of peripheral blood circulating tumor cells | |
WO2021213297A1 (en) | Immunofluorescence test kit for measuring pd-l1 gene mutations in circulating tumor cells in peripheral blood in non-small cell lung cancer patient, and method for same | |
CN111679077A (en) | Immunofluorescence kit for expressing E-Cadherin (circulating tumor cell) in peripheral blood of renal cell carcinoma patient and detection method | |
WO2021213299A1 (en) | Kit for detecting pd-l1 gene mutation of peripheral blood circulating tumor cells of prostate cancer patient and detection method | |
WO2022001826A1 (en) | Immunofluorescence kit for detecting e-cadherin expression of peripheral blood circulating tumor cells of patient with pancreatic cancer | |
WO2021213261A1 (en) | Kit and detection method for detecting pd-l1 gene mutations in peripheral blood circulating tumor cells of patient with gastric cancer | |
WO2021213298A1 (en) | Immunofluorescence kit for detecting ca199 expression of peripheral blood circulating tumor cells of pancreatic cancer patient and detection method | |
WO2021213318A1 (en) | Non-diagnostic method for measuring braf gene v600e mutations in colorectal cancer patient by means of circulating tumor cells in peripheral blood | |
WO2022001823A1 (en) | Kit and method for detecting e-cadherin gene mutations in circulating tumor cells in peripheral blood of patient with non-small cell lung cancer | |
WO2022001825A1 (en) | Kit for detecting e-cadherin expression of peripheral blood circulating tumor cells of pancreatic cancer patient and detection method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21791984 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21791984 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21791984 Country of ref document: EP Kind code of ref document: A1 |